Safety and efficacy of Omacor in severe hypertriglyceridemia

William Harris, Henry N. Ginsberg, Narin Arunakul, Neil S. Shachter, Sheryl L. Windsor, Marian Adams, Lars Berglund, Karin Osmundsen

Research output: Contribution to journalArticle

270 Citations (Scopus)

Abstract

Background: Severe hypertriglyceridemia is a risk factor for acute pancreatitis, therefore decreasing serum triglyceride concentrations is an important component of risk management. Omega-3 fatty acids are well known hypotriglyceridemic agents, but their efficacy in severe forms of the disorder is not well documented. Our objective was to examine the effects of Omacor, a drug composed of 85% omega-3 fatty acid ethyl esters. Methods: Forty-two patients with triglyceride concentrations between 5.65 and 22.60 mmol/l (500 and 2000 mg/dl) were studied in a prospective, double-blind, placebo-controlled trial of Omacor (4 g/day for 4 months). Results: Compared with baseline values, Omacor significantly reduced mean triglyceride concentrations by 45% (P

Original languageEnglish (US)
Pages (from-to)385-391
Number of pages7
JournalJournal of Cardiovascular Risk
Volume4
Issue number5-6
StatePublished - 1997
Externally publishedYes

Fingerprint

Hypertriglyceridemia
Triglycerides
Omega-3 Fatty Acids
Safety
Risk Management
Pancreatitis
Esters
Placebos
Serum
Pharmaceutical Preparations
Omacor

Keywords

  • Docosahexaenoic acid
  • Eicosapentaenoic acid
  • Fish oil
  • Hypertriglyceridemia
  • Pancreatitis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Harris, W., Ginsberg, H. N., Arunakul, N., Shachter, N. S., Windsor, S. L., Adams, M., ... Osmundsen, K. (1997). Safety and efficacy of Omacor in severe hypertriglyceridemia. Journal of Cardiovascular Risk, 4(5-6), 385-391.

Safety and efficacy of Omacor in severe hypertriglyceridemia. / Harris, William; Ginsberg, Henry N.; Arunakul, Narin; Shachter, Neil S.; Windsor, Sheryl L.; Adams, Marian; Berglund, Lars; Osmundsen, Karin.

In: Journal of Cardiovascular Risk, Vol. 4, No. 5-6, 1997, p. 385-391.

Research output: Contribution to journalArticle

Harris, W, Ginsberg, HN, Arunakul, N, Shachter, NS, Windsor, SL, Adams, M, Berglund, L & Osmundsen, K 1997, 'Safety and efficacy of Omacor in severe hypertriglyceridemia', Journal of Cardiovascular Risk, vol. 4, no. 5-6, pp. 385-391.
Harris W, Ginsberg HN, Arunakul N, Shachter NS, Windsor SL, Adams M et al. Safety and efficacy of Omacor in severe hypertriglyceridemia. Journal of Cardiovascular Risk. 1997;4(5-6):385-391.
Harris, William ; Ginsberg, Henry N. ; Arunakul, Narin ; Shachter, Neil S. ; Windsor, Sheryl L. ; Adams, Marian ; Berglund, Lars ; Osmundsen, Karin. / Safety and efficacy of Omacor in severe hypertriglyceridemia. In: Journal of Cardiovascular Risk. 1997 ; Vol. 4, No. 5-6. pp. 385-391.
@article{95fb4f99158a456e9544747f95f976f2,
title = "Safety and efficacy of Omacor in severe hypertriglyceridemia",
abstract = "Background: Severe hypertriglyceridemia is a risk factor for acute pancreatitis, therefore decreasing serum triglyceride concentrations is an important component of risk management. Omega-3 fatty acids are well known hypotriglyceridemic agents, but their efficacy in severe forms of the disorder is not well documented. Our objective was to examine the effects of Omacor, a drug composed of 85{\%} omega-3 fatty acid ethyl esters. Methods: Forty-two patients with triglyceride concentrations between 5.65 and 22.60 mmol/l (500 and 2000 mg/dl) were studied in a prospective, double-blind, placebo-controlled trial of Omacor (4 g/day for 4 months). Results: Compared with baseline values, Omacor significantly reduced mean triglyceride concentrations by 45{\%} (P",
keywords = "Docosahexaenoic acid, Eicosapentaenoic acid, Fish oil, Hypertriglyceridemia, Pancreatitis",
author = "William Harris and Ginsberg, {Henry N.} and Narin Arunakul and Shachter, {Neil S.} and Windsor, {Sheryl L.} and Marian Adams and Lars Berglund and Karin Osmundsen",
year = "1997",
language = "English (US)",
volume = "4",
pages = "385--391",
journal = "European Journal of Preventive Cardiology",
issn = "2047-4873",
publisher = "SAGE Publications Ltd",
number = "5-6",

}

TY - JOUR

T1 - Safety and efficacy of Omacor in severe hypertriglyceridemia

AU - Harris, William

AU - Ginsberg, Henry N.

AU - Arunakul, Narin

AU - Shachter, Neil S.

AU - Windsor, Sheryl L.

AU - Adams, Marian

AU - Berglund, Lars

AU - Osmundsen, Karin

PY - 1997

Y1 - 1997

N2 - Background: Severe hypertriglyceridemia is a risk factor for acute pancreatitis, therefore decreasing serum triglyceride concentrations is an important component of risk management. Omega-3 fatty acids are well known hypotriglyceridemic agents, but their efficacy in severe forms of the disorder is not well documented. Our objective was to examine the effects of Omacor, a drug composed of 85% omega-3 fatty acid ethyl esters. Methods: Forty-two patients with triglyceride concentrations between 5.65 and 22.60 mmol/l (500 and 2000 mg/dl) were studied in a prospective, double-blind, placebo-controlled trial of Omacor (4 g/day for 4 months). Results: Compared with baseline values, Omacor significantly reduced mean triglyceride concentrations by 45% (P

AB - Background: Severe hypertriglyceridemia is a risk factor for acute pancreatitis, therefore decreasing serum triglyceride concentrations is an important component of risk management. Omega-3 fatty acids are well known hypotriglyceridemic agents, but their efficacy in severe forms of the disorder is not well documented. Our objective was to examine the effects of Omacor, a drug composed of 85% omega-3 fatty acid ethyl esters. Methods: Forty-two patients with triglyceride concentrations between 5.65 and 22.60 mmol/l (500 and 2000 mg/dl) were studied in a prospective, double-blind, placebo-controlled trial of Omacor (4 g/day for 4 months). Results: Compared with baseline values, Omacor significantly reduced mean triglyceride concentrations by 45% (P

KW - Docosahexaenoic acid

KW - Eicosapentaenoic acid

KW - Fish oil

KW - Hypertriglyceridemia

KW - Pancreatitis

UR - http://www.scopus.com/inward/record.url?scp=0031425356&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031425356&partnerID=8YFLogxK

M3 - Article

C2 - 9865671

AN - SCOPUS:0031425356

VL - 4

SP - 385

EP - 391

JO - European Journal of Preventive Cardiology

JF - European Journal of Preventive Cardiology

SN - 2047-4873

IS - 5-6

ER -